Savara, Inc. (SVRA)

Over the past six months, Savara's stock price has been impacted by several events. The FDA extended the review period for molgramostim's BLA, causing an initial stock dip. The UK's MHRA accepted Savara's marketing authorization application for MOLBREEVI. Savara announced presentations of new IMPALA-2 Phase 3 data at the ATS 2026 International Conference. The company disclosed equity inducement grants to new hires, signaling commercial buildout. Savara's Q4 2025 EPS missed estimates. Analyst ratings have been mixed but generally lean positive. Savara priced a $130 million equity offering in October 2025. Savara Inc. saw its stock tick higher amid takeover speculation. The stock has experienced fluctuations, and as of May 7, 2026, Savara's stock price was $5.17.

Specific details regarding demand seasonality for Savara, Inc.'s products and services are not explicitly provided. As a clinical-stage biopharmaceutical company, demand for its investigational therapy would be driven by clinical trial enrollment and market access strategies rather than typical seasonal consumer patterns.

Savara, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Their primary product candidate is molgramostim nebulizer solution (MOLBREEVI), an inhaled biologic in Phase 3 clinical development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara Inc.'s corporate office is located in Langhorne, Pennsylvania, United States. The company is also actively engaged in market development in Europe, specifically the EU4+UK region, where the aPAP ClearPath antibody test has been launched. Additionally, patients from Europe, the UK, and Turkey are enrolled in the IMPALA-2 clinical trial.

Information specifically detailing Savara, Inc.'s brand reputation is not readily available. The available data focuses more on regulatory milestones, clinical trial progress, and financial performance.

Savara, Inc.'s ownership is primarily institutional, with major holders including NEA Management Company, LLC, Bain Capital Life Sciences Investors, LLC, and others. Individual investors also hold shares, with James E. Flynn owning the most shares.